Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 150

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 150
---
 applicators
within our range:

The Alpha DaRT Needle Applicator and components
(18 gauge needle, 140 mm in length)

The Alpha DaRT Flex Applicator

The Alpha DaRT Template Applicator

Loading Device

Our Accessories

In addition to our sources
and applicators, we have also developed a number of ancillary accessories specially designed for use with our Alpha DaRT sources, including
grids for guiding deployment, surgical buttons and clips. We have also developed and printed personalized bolus templates for use in specific
clinical cases, designed to allow the clinician to execute the treatment plan accurately and seamlessly in conjunction with the Alpha
DaRT Template Applicator.

Under a collaboration agreement
signed in August 2022 with MIM Software Inc. (“ MIM”) we collaborate with MIM on the use of MIM’s radiation treatment
planning software suite, including MIM Symphony and MIMcloud®, for development of new features and support for the Alpha
DaRT across multiple potential indications, integration into all clinical trials involving the Alpha DaRT, and bundling the MIM software
with the Alpha DaRT for future commercial sales in territories where the Alpha DaRT and MIM’s software are both approved. The agreement
contemplates certain payments to be made by us to MIM in the future upon further development of MIM’s software and integration with
the Alpha DaRT in new geographies or sites or with additional features, and upon commercial sales of the Alpha DaRT bundled with MIM software.

Our Manufacturing and Supply Infrastructure

The Alpha DaRT technology
utilizes sources enriched with Radium-224, a radioactive material with a half-life of only 3.7 days. As each treatment requires a different
number of sources and applicators tailored for the specific patient, a reliable and timely delivery of the personalized Alpha DaRT kit
to the hospital is required. We therefore plan to develop production sites in key regions around the world. We have already built two
sites in the United States and Israel, have started the planning process for additional sites in the U. S., Israel, and Japan, and anticipate
that we may build another facility in Europe. Our global manufacturing plan is designed to ensure a sufficient supply of radioactive sources
with fast and cost-efficient delivery to our core markets.

Our key input for production
of the Alpha DaRT is Thorium-228, a readily available radioisotope that can be purchased from licensed vendors around the world. Thorium-228